Executives in Residence
MSIP’s Executive in Residence (EIR) program connects Mount Sinai Health System innovators and technologies with seasoned industry executives in healthcare, venture capital and serial entrepreneurs. Our EIR’s form close working relationships with MSIP’s business development team and Mount Sinai inventor’s in an effort to lend domain expertise to bring Mount Sinai technologies to market.
Ron invests in the biotechnology and molecular diagnostic sectors. He has served on the boards of eighteen companies including General Surgical Innovations, Inc. (acquired by Tyco International Corp.), GeneOhm Sciences, Inc. (acquired by Becton Dickinson), Protometrix, Inc. (acquired by Invitrogen Corp.), and Applied Molecular Evolution Inc. (acquired by Eli Lilly). He was founding Chairman of Amicus Therapeutics (NASDAQ: FOLD) and Chairman of Bikam Therapeutics (responsible for sale to Shire in 2014). He also was CEO of Protometrix, Inc. as well as of CGI Pharmaceuticals, Inc.
Prior to the founding of CHL Medical Partners, Ron was a general partner at Hancock Venture Partners (now HarbourVest Partners) where he invested in sixteen healthcare companies, ten of which had successful IPOs.
Ron graduated from the University of Glasgow with a B.Sc. in Molecular Biology, Oxford University where he received a D.Phil. in Cell Biology and the Wharton School of the University of Pennsylvania.
Lisa Wisniewski is a drug development executive and thought leader whose scientific, regulatory, operational and business experience uniquely positions her to assess, develop and optimize pharmaceutical strategy. She has over 20 years of global experience driving the development and execution of pharmaceutical strategy, developing and leading teams and transformations that have delivered significant results in multiple therapeutic areas including oncology, anti-infectives, vaccines and pulmonary hypertension. Lisa’s experience includes small molecules, proteins, monoclonal antibodies and devices in all research and development phases.
Lisa received her BS from University of Illinois and her MS and PhD from North Carolina State University, where she graduated Xi Sigma Pi and Sigma Xi, respectively. Following her PhD, she completed a post-doc at Washington University in St Louis.
J. Mark Junewicz is founder and President of Junewicz & Co., which provides private investment banking services to private and public companies in the Life Sciences Industry – Biopharmaceuticals and Medical Devices. Junewicz & Co. provides merger & acquisition, product licensing and strategic advisory services and advises companies on IPOs and equity financings. Clients have ranged from start-ups to public companies with markets caps > $4 billion. Clients which have achieved successful exits include Kos Pharmaceuticals (acquired by Abbott), Medicis Pharmaceuticals (acquired by Valeant), Gentium S.p.A. (acquired by Jazz Pharmaceuticals), Richwood Pharmaceutical Company (ADHD drug ADDERALL® acquired Shire plc), and Animas Corporation (acquired by Johnson & Johnson).
Prior to forming Junewicz & Co. in 1990, Mark was a Managing Director in investment banking at Merrill Lynch and Bear Steans. Mark also serves as a Senior Advisor to Brookline Capital Markets. Mark was previously a member of the Advisory Board of Ignyta, Inc., a developer of precision therapeutics for cancer treatment, which was acquired in February 2018 by Roche Holdings.
Mark received his M.B.A. from The Wharton School of the University of Pennsylvania and a B.S., cum laude, in Economics from the University of Pennsylvania.
Dr. Ianchulev is a prolific inventor, innovator, physician-executive and public health expert with deep life science and medical technology expertise covering the spectrum of biotech and med-tech. As an innovator, technology developer, and investor he has been at the core of medical products and technologies which have transformed the ophthalmic field and are impacting medical care for hundreds of thousands of patients every year. While at Genentech, Dr. Ianchulev headed the ophthalmology research group and directed the development and the FDA approval of Lucentis, the most successful specialty biologic in the field of ophthalmology with more than $4B of annual sales.
Dr. Ianchulev is also the inventor of the first ophthalmic intraoperative biometry device, ORA – intraoperative aberrometry for high precision, infrared laser-guided cataract surgery, which dramatically improved the outcomes of cataract surgery with more than half a million patients treated to date. Dr. Ianchulev was the patent holder and technology founder of Wavetec Inc., which was acquired by Alcon/Novartis.
In the glaucoma field, Dr. Ianchulev led all research and development efforts of the first suprachoroidal micro-stent (CyPass). As the Chief Medical Officer and the head of research and development for Transcend Medical (acquired by Alcon/Novartis) he has been at the forefront of next generation MIGS (Micro-Incisional Glaucoma Surgery) innovation and oversaw one of the largest glaucoma surgical research programs.
As the founder of Eyenovia Bio (www.eyenoviabio.com), Dr. Ianchulev is also spearheading new technology for piezostatic high-precision micro-therapeutics and as the founder of Iantech, Inc. he is the inventor of micro-interventional, energy-free, phaco-fragmentation for cataract surgery. He is also a managing partner at Private Medical Equity, a private equity firm for managed direct investments.
Dr. Ianchulev is the president of the KeepYourSight.org foundation, the first e-public health foundation for online vision screening of glaucoma and macular disease. Utilizing new breakthrough technology for virtual online screening, KeepYourSight helps thousands of people every year to stop preventable blindness.
For his leadership in public health, innovation and medicine, Dr. Ianchulev was an invited expert by Congress during the deliberations on medical innovation and FDA regulation. Dr. Ianchulev received both his medical degree and a master’s of public health from Harvard University and completed his specialty training at the Doheny Eye Institute, University of Southern California.
Dr. Ianchulev is a holder of multiple issued and pending patents. He has multiple high-impact publications in the field, which have been cited by more than 2,000 peer-reviewed publications. He also sits on a number of corporate and advisory Boards.